Study ID
Age median, (IQR), Male %
TCZ arm (follow up)
Routine treatment
Outcomes (combinable and not combinable)
Events TCZ (control) Events TCZ (control)
Campochiaro C. et al (Campochiaro et al., 2020)
TCZ: 64 (53 – 75), 90.6 Control: 60 (55-75.5), 81.8
IV 400 mg once, 2nd dose if needed (28 days)
HCQ, lopinavir/ritonavir, ceftriaxone, azithromycin, enoxaparin
1-Mortality
5/32 (11/33)
5/32 (11/33)
2- Requirement of MV 0/32 (3/33) 0/32 (3/33)
3- Hospital Discharge 20/32 (16/33) 20/32 (16/33)
4- Clinical improvement 22/32 (20/33) 22/32 (20/33)
5- Serious adverse events 8/32 (9/33) 8/32 (9/33)
6- Bacteremia 4/32 (4/33) 4/32 (4/33)
7- pulmonary embolism 2/32 (3/33) 2/32 (3/33)
8- Elevated liver functions 5/32 (6/33) 5/32 (6/33)
9- Neutropenia 5/32 (0/33) 5/32 (0/33)
10- Changes in respiratory support
Improved 24/32 (20/33) Worsened 5/32 (12/33) No change 3/32 (1/33) Improved 24/32 (20/33) Worsened 5/32 (12/33) No change 3/32 (1/33)
Guaraldi G. et al (Guaraldi et al., 2020)
TCZ: 63 (54–72), 72.7 Control: 69 (57–78), 63.6
IV 8mg/kh, Max 800, twice (14 days)
Oxygen supply, HCQ, azithromycin, lopinavir–ritonavir and low molecular weight heparin
1-Mortality
6/88 (73/365)
6/88 (73/365)
2- Requirement of MV 16/88 (57/365) 16/88 (57/365)
3- Serious adverse events 1/179 (0/365) 1/179 (0/365)
5- Bacteremia 3/179 (4/365) 3/179 (4/365)
6- New infections 24/179 (14/965) 24/179 (14/965)
7- Elevated liver functions 0/179 (1/365) 0/179 (1/365)
8- Neutropenia 1/179 (0/365) 1/179 (0/365)
Colaneri M. et al (Colaneri et al., 2020)
TCZ: 63.74 (16.32), 90.5 Control: 62.33 (18.68), 69.2
IV 8mg/kh, Max 800, twice (7 days)
HCQ, azithromycin, low weight heparin, and methylprednisolone
1-Mortality
5/21 (19/91)
5/21 (19/91)
2- ICU admission 3/21 (12/91) 3/21 (12/91)
Kewan T. et al (Kewan et al., 2020)
TCZ: 62 (53- 71), 71.4 Control: 62 (53 - 71), 47.8
IV 8mg/kh, Max 400 (21 days)
HCQ, Azithromycin
1-Mortality
3/28 (2/23)
3/28 (2/23)
2- Requirement of MV 2/9 (6/18) 2/9 (6/18)
3- Hospital Discharge 11/28 (13/23) 11/28 (13/23)
4- Clinical improvement 18/28 (13/23) 18/28 (13/23)
5- New infections 5/28 (5/23) 5/28 (5/23)
6- Changes in respiratory support
Improved 18/28 (13/23) Worsened 5/28 (6/23) No change 5/28 (4/23) Improved 18/28 (13/23) Worsened 5/28 (6/23) No change 5/28 (4/23)
Somers EC. et al (Somers, Eschenauer, Troost, Golob, Gandhi, Wang, Zhou, Petty, Baang, Dillman, et al., 2020)
TCZ: 55 ± 14.9, 68 Control: 60 ± 14.5, 64.5 8 mg/kg (maximum 800 mg) once (28 days)
HCQ, Redmsivir (only 2 patients in each group, NSAIDs, Acetaminophen and anticoagulants
1- Mortality
14/78 (27/76)
14/78 (27/76)
2- New infections 42/78 (20/76) 42/78 (20/76)
Ip A. et al (Ip et al., 2020)
TCZ: 62 (53–70), 73.9 Control: 69 (58–77), 62.2
IV 400mg single, second dose given to small number of patients (28 days)
HCQ, azithromycin
1-Mortality
1-Mortality
12/134 (25/413)
2- Bacteremia 2- Bacteremia 60/134 (227/413)
3- New infections 3- New infections 12/134 (25/413)